Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
Explore this paper's citation graph
Summary
Overall, it is found that a significant proportion of UMs express PD-L1 and provide molecular support for using checkpoint inhibitors as a treatment approach for this class of tumors.
- Type
- article
- Published
- 2018-12-01
- Cited by
- 5
- References
- 35
- OpenAlex
- https://openalex.org/W2839753868
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:54471284
Keywords
PD-L1, Immune checkpoint, Blockade, Malignancy, Fluorescence in situ hybridization
References
- PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
- Massively‐parallel sequencing assists the diagnosis and guided treatment of cancers of unknown primary
- Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases
- Pembrolizumab for the treatment of non-small-cell lung cancer.
- The Stanford Tissue Microarray Database
- Cancer of unknown primary site.
- Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
- Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
- Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
- Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer
- Nivolumab versus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer
- Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Immune checkpoint blockade: a common denominator approach to cancer therapy
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies.
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
- Genetic Basis for PD-L1 Expression in Squamous Cell Carcinomas of the Cervix and Vulva.
- CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity
Cited by
- Human Germinal Center–associated Lymphoma (HGAL) Is a Reliable Marker of Normal and Neoplastic Follicular Helper T Cells Including Angioimmunoblastic T-Cell Lymphoma
- Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas
- Sarcomatoid carcinoma transformation in oral undifferentiated carcinoma following sequential immune combined targeted therapy: a case report
- Expression of CD47 protein in hematolymphoid neoplasms: Implications for CD47-mediated cancer immunotherapy.
- CD47 Expression in Classic Follicular Lymphoma is Associated with Event-Free Survival.
- Cd47 Expression in Follicular Lymphoma is Associated with Progression-Free Survival
Related papers
- Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer
- Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer
- A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade.
- Mechanisms of Resistance to PD-1 and PD-L1 blockade
- Tumor organoid-originated biomarkers predict immune response to PD-1 blockade.
- Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
- A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report
- Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy.
- Potential biomarker for checkpoint blockade immunotherapy and treatment strategy
- The Role of Pd-L1 on Tumor Cells in Host Immune System Escape and Tumor Immunotherapy by Pd-L1 Blockade; Immune Checkpoint Blockade in Cancer Immunotherapy